Ralph Smalling Biography and Net Worth

Vice President, Head of Regulatory Affairs of Genelux

Mr. Smalling is currently serving as Vice President, Head of Regulatory Affairs since 2023. Prior to that, he was consulting as Head of Regulatory Affairs since 2014.

Mr. Smalling has over 40 years of experience in the biopharmaceutical industry, with expertise in all aspects of Regulatory development.

Previously, he served at Amgen in positions of increasing responsibility, including Vice President of Regulatory Affairs and International Safety. Under his leadership, Amgen obtained marketing authorizations, supplemental approvals and orphan drug designations in the US, EU, Canada and Australia for numerous products. Mr. Smalling was a member of the industry team that negotiated PDUFA II and drafted several of the provisions included in the FDAMA legislation passed by Congress in 1997.

Mr. Smalling earned a Master of Science in Microbiology from California State University, Long Beach, and a Bachelor of Arts degree in Biology from Occidental College.

What is Ralph Smalling's net worth?: The estimated net worth of Ralph Smalling is at least $194.72 thousand as of June 3rd, 2026. Mr. Smalling owns 67,611 shares of Genelux stock worth more than $194,720 as of August 27th. This net worth approximation does not reflect any other assets that Mr. Smalling may own. Learn More about Ralph Smalling's net worth.
How do I contact Ralph Smalling?: The corporate mailing address for Mr. Smalling and other Genelux executives is 2625 Townsgate Road Suite 230, Westlake Village CA, 91361. Genelux can also be reached via phone at 805-267-9889 and via email at [email protected]. Learn More on Ralph Smalling's contact information.
Has Ralph Smalling been buying or selling shares of Genelux?: Ralph Smalling has not been actively trading shares of Genelux in the last ninety days. Most recently, Ralph Smalling sold 192 shares of the business's stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $2.93, for a transaction totalling $562.56. Following the completion of the sale, the insider now directly owns 67,611 shares of the company's stock, valued at $198,100.23. Learn More on Ralph Smalling's trading history.
Who are Genelux's active insiders?: Genelux's insider roster includes Ralph Smalling (Vice President, Head of Regulatory Affairs), John Smither (Director), John Thomas (Director), and James Tyree (Director). Learn More on Genelux's active insiders.
Are insiders buying or selling shares of Genelux?: In the last year, insiders at the sold shares 15 times. They sold a total of 56,111 shares worth more than $199,950.70. The most recent insider tranaction occured on August, 4th when insider Yong Yu sold 653 shares worth more than $1,919.82. Insiders at Genelux own 7.5% of the company. Learn More about insider trades at Genelux.
Information on this page was last updated on 8/4/2026.

Ralph Smalling Insider Trading History at Genelux

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/3/2026	Sell	192	$2.93	$562.56	67,611
5/11/2026	Sell	270	$2.98	$804.60	67,803
12/5/2025	Sell	165	$4.69	$773.85	68,658
11/17/2025	Sell	343	$5.37	$1,841.91	68,823
9/3/2025	Sell	580	$3.36	$1,948.80	69,166
8/21/2025	Sell	1,244	$3.36	$4,179.84	69,746

Ralph Smalling Buying and Selling Activity at Genelux

Genelux Company Overview

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Today's Range

Now: $2.88

$2.72

$2.95

50 Day Range

MA: $2.85

$2.51

$3.05

2 Week Range

Now: $2.88

$2.29

$8.53

Volume

592,424 shs

Average Volume

232,765 shs

Market Capitalization

$130.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.6